T-lymphocyte therapy for malignant disease has been the focus of a great deal of basic and clinical research for nearly two decades, although much of this work has focused on augmentation of adaptive immunity. Growing evidence suggests that gd T cells form part of the innate immune defense and are potent antitumor effectors, especially against leukemia, 1-4 lymphoma 5, 6 and myeloma. 7 Although a number of in vitro and in vivo studies suggest that gd T cells might be ideally suited for immunotherapeutic applications specifically in the context of hematopoietic stem cell transplantation (HSCT), no studies have specifically addressed the role of gd T-cell therapy in this setting to date.
Smetak et al. 8 have developed a current good manufacturing practice (cGMP) compatible validated method for enriching innate immune effector lymphocytes which should provide clinicians with the means to deliver NK and gd T-cell therapy. This is a welcome addition to previous methods which relied on soluble anti-ab monoclonal antibodies and rabbit complement to achieve the same goal. 9 Our group validated CD4/CD8 T-cell depletion using similar techniques for a donor innate lymphocyte infusion (DILI) clinical trial intended for prophylaxis against relapse for high-risk acute leukemia in an ongoing pediatric BMT trial (BB IDE 13041). We found that the B-cell content of the graft to be unacceptably high, requiring us to administer large doses of B cells to achieve the gd and NK doses required by the trial. Table 1 shows the pre-and post-depletion graft composition from one donor. Since our trial requires DILI to be administered 40-60 days following BMT, we were concerned that the infusion of large numbers of B cells to immunosuppressed patients soon following transplant could place some patients at risk for EBV-associated post transplant lymphoproliferative disease (PTLD). We therefore will be adding a step to deplete B cells using CD19-coated ferromagnetic microspheres (Miltenyi, Auburn, CA, USA) before initiating patient accrual.
We would appreciate further discussion on the potential impact of B-cell content of their final cell product and the risk EBV PTLD. The authors discussed options for further manipulation of the product such as ex vivo Zoledronate/ IL-2 expansion of Vd2 þ cells, which would eliminate the need for B-cell depletion as the B cells do not survive the culture conditions required for gd T-cell expansion.
Administration of the product beyond the first 6 months following hematopoietic stem cell transplantation would also diminish the risk of EBV PTLD assuming normal immune reconstitution. We thank the authors for this important contribution and would appreciate further discussion of its clinical application in response to our concerns. 
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